Read about an industry partnership combining AI-driven peptide design with formulation expertise to advance orally deliverable peptide therapeutics.
Key Takeaways
- LG AI Research signed a master agreement with D&D Pharmatech on 17 June 2026
- While D&D Pharmatech will handle structural design
- LG AI Research will also leverage its EXAONE Discovery and other biology AI initiatives